Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1987 Apr;90(4):771–783. doi: 10.1111/j.1476-5381.1987.tb11231.x

Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists.

P J Piper, A G Stewart
PMCID: PMC1917207  PMID: 3034369

Abstract

Platelet-activating factor (Paf) is a potent coronary vasoconstrictor in rat, guinea-pig, dog and pig. The present study investigated the mechanism and duration of Paf in guinea-pig isolated, Krebs-perfused hearts. Dose-related and sustained decreases in cardiac contractility and increases in coronary perfusion pressure were elicited by bolus doses of Paf (0.3-100 pmol). Platelet-activating factor (30 pmol) induced increases in the production of immunoreactive thromboxane B2 (TXB2), leukotriene B4 (LTB4) and LTC4, but not 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha). In addition, the release of leukotriene-like material following Paf was observed using on-line superfusion bioassay. The coronary vasoconstrictor actions of Paf were partially antagonized by the leukotriene receptor antagonist, FPL 55712 (1.9 microM), or by indomethacin (2.8 microM). The combined use of these compounds did not result in further significant inhibition. The Paf receptor antagonists, BN 52021 (30 microM) and L 652, 731 (10 microM), antagonized both the increase in coronary perfusion pressure and the decrease in cardiac contractility induced by Paf (10-100 pmol) in a surmountable and relatively selective manner. The effects of a bolus dose of 100 pmol Paf were sustained in excess of 18 min. Exogenous Paf underwent little metabolism on passing through the coronary circulation with only 2% being converted to lyso-Paf and approximately 4% being retained by the heart after 18 min of perfusion. These results suggest that the coronary vasoconstrictor actions of Paf are partially dependent on the release of vasoactive arachidonic acid metabolites. The extraordinary potency and the long-lasting action of Paf indicate a potential role for this pro-inflammatory mediator in disorders of the coronary circulation.

Full text

PDF
781

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aehringhaus U., Peskar B. A., Wittenberg H. R., Wölbling R. H. Effect of inhibition of synthesis and receptor antagonism of SRS-A in cardiac anaphylaxis. Br J Pharmacol. 1983 Sep;80(1):73–80. doi: 10.1111/j.1476-5381.1983.tb11051.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allan G., Levi R. The cardiac effects of prostaglandins and their modification by the prostaglandin antagonist N-0164. J Pharmacol Exp Ther. 1980 Jul;214(1):45–49. [PubMed] [Google Scholar]
  3. Allan G., Levi R. Thromboxane and prostacyclin release during cardiac immediate hypersensitivity reactions in vitro. J Pharmacol Exp Ther. 1981 Apr;217(1):157–161. [PubMed] [Google Scholar]
  4. Anhut H., Bernauer W., Peskar B. A. Pharmacological modification of thromboxane and prostaglandin release in cardiac anaphylaxis. Prostaglandins. 1978 May;15(5):889–900. doi: 10.1016/0090-6980(78)90156-9. [DOI] [PubMed] [Google Scholar]
  5. Barst S., Mullane K. The release of a leukotriene D4-like substance following myocardial infarction in rabbits. Eur J Pharmacol. 1985 Aug 27;114(3):383–387. doi: 10.1016/0014-2999(85)90384-x. [DOI] [PubMed] [Google Scholar]
  6. Beaubien B. B., Tippins J. R., Morris H. R. Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide. Biochem Biophys Res Commun. 1984 Nov 30;125(1):105–108. doi: 10.1016/s0006-291x(84)80340-x. [DOI] [PubMed] [Google Scholar]
  7. Benveniste J., Boullet C., Brink C., Labat C. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol. 1983 Sep;80(1):81–83. doi: 10.1111/j.1476-5381.1983.tb11052.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Benveniste J. Paf-acether (platelet-activating factor). Adv Prostaglandin Thromboxane Leukot Res. 1985;13:11–18. [PubMed] [Google Scholar]
  9. Bessin P., Bonnet J., Apffel D., Soulard C., Desgroux L., Pelas I., Benveniste J. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol. 1983 Jan 21;86(3-4):403–413. doi: 10.1016/0014-2999(83)90190-5. [DOI] [PubMed] [Google Scholar]
  10. Bourgain R. H., Maes L., Braquet P., Andries R., Touqui L., Braquet M. The effect of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (paf-acether) on the arterial wall. Prostaglandins. 1985 Aug;30(2):185–197. doi: 10.1016/0090-6980(85)90184-4. [DOI] [PubMed] [Google Scholar]
  11. Cervoni P., Herzlinger H. E., Lai F. M., Tanikella T. K. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. Br J Pharmacol. 1983 Jul;79(3):667–671. doi: 10.1111/j.1476-5381.1983.tb10003.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chap H., Mauco G., Simon M. F., Benveniste J., Douste-Blazy L. Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets. Nature. 1981 Jan 22;289(5795):312–314. doi: 10.1038/289312a0. [DOI] [PubMed] [Google Scholar]
  13. Chignard M., Le Couedic J. P., Tence M., Vargaftig B. B., Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature. 1979 Jun 28;279(5716):799–800. doi: 10.1038/279799a0. [DOI] [PubMed] [Google Scholar]
  14. Cocks T. M., Angus J. A. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature. 1983 Oct 13;305(5935):627–630. doi: 10.1038/305627a0. [DOI] [PubMed] [Google Scholar]
  15. Doebber T. W., Wu M. S., Biftu T. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731. J Immunol. 1986 Jun 15;136(12):4659–4668. [PubMed] [Google Scholar]
  16. Evers A. S., Murphree S., Saffitz J. E., Jakschik B. A., Needleman P. Effects of endogenously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest. 1985 Mar;75(3):992–999. doi: 10.1172/JCI111801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fitzgerald M. F., Moncada S., Parente L. The anaphylactic release of platelet-activating factor from perfused guinea-pig lungs. Br J Pharmacol. 1986 May;88(1):149–153. doi: 10.1111/j.1476-5381.1986.tb09481.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gorman R. R., Morton D. R., Hopkins N. K., Lin A. H. Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis and cyclic AMP accumulation in human polymorphonuclear leukocytes. Adv Prostaglandin Thromboxane Leukot Res. 1983;12:57–63. [PubMed] [Google Scholar]
  19. Gryglewski R. J., Moncada S., Palmer R. M. Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol. 1986 Apr;87(4):685–694. doi: 10.1111/j.1476-5381.1986.tb14586.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Harker L. A. Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation. 1986 Feb;73(2):206–223. doi: 10.1161/01.cir.73.2.206. [DOI] [PubMed] [Google Scholar]
  21. Hattori Y., Levi R. Effect of PGD2 on cardiac contractility: a negative inotropism secondary to coronary vasoconstriction conceals a primary positive inotropic action. J Pharmacol Exp Ther. 1986 Jun;237(3):719–724. [PubMed] [Google Scholar]
  22. Hellewell P. G., Williams T. J. A specific antagonist of platelet-activating factor suppresses oedema formation in an Arthus reaction but not oedema induced by leukocyte chemoattractants in rabbit skin. J Immunol. 1986 Jul 1;137(1):302–307. [PubMed] [Google Scholar]
  23. Hwang S. B., Lam M. H., Biftu T., Beattie T. R., Shen T. Y. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. J Biol Chem. 1985 Dec 15;260(29):15639–15645. [PubMed] [Google Scholar]
  24. Hwang S. B., Lam M. H., Li C. L., Shen T. Y. Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema. Eur J Pharmacol. 1986 Jan 14;120(1):33–41. doi: 10.1016/0014-2999(86)90636-9. [DOI] [PubMed] [Google Scholar]
  25. Jackson C. V., Schumacher W. A., Kunkel S. L., Driscoll E. M., Lucchesi B. R. Platelet-activating factor and the release of a platelet-derived coronary artery vasodilator substance in the canine. Circ Res. 1986 Feb;58(2):218–229. doi: 10.1161/01.res.58.2.218. [DOI] [PubMed] [Google Scholar]
  26. Kenzora J. L., Pérez J. E., Bergmann S. R., Lange L. G. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest. 1984 Oct;74(4):1193–1203. doi: 10.1172/JCI111528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lefer A. M., Müller H. F., Smith J. B. Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol. 1984 Sep;83(1):125–130. doi: 10.1111/j.1476-5381.1984.tb10126.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lefer A. M., Roth D. M. Absence of direct inotropic effects of peptide leukotrienes in isolated mammalian heart preparations. Prog Clin Biol Res. 1985;199:59–70. [PubMed] [Google Scholar]
  29. Lefer A. M., Roth D. M., Lefer D. J., Smith J. B. Potentiation of leukotriene formation in pulmonary and vascular tissue. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jun;326(2):186–189. doi: 10.1007/BF00517318. [DOI] [PubMed] [Google Scholar]
  30. Letts L. G., Piper P. J. Cardiac actions of leukotrienes B4, C4, D4, and E4 in guinea pig and rat in vitro. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:391–395. [PubMed] [Google Scholar]
  31. Letts L. G., Piper P. J. The actions of leukotrienes C4 and D4 on guinea-pig isolated hearts. Br J Pharmacol. 1982 May;76(1):169–176. doi: 10.1111/j.1476-5381.1982.tb09203.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Levi R., Burke J. A., Guo Z. G., Hattori Y., Hoppens C. M., McManus L. M., Hanahan D. J., Pinckard R. N. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res. 1984 Feb;54(2):117–124. doi: 10.1161/01.res.54.2.117. [DOI] [PubMed] [Google Scholar]
  33. Montrucchio G., Camussi G., Tetta C., Emanuelli G., Orzan F., Libero L., Brusca A. Intravascular release of platelet-activating factor during atrial pacing. Lancet. 1986 Aug 2;2(8501):293–293. doi: 10.1016/s0140-6736(86)92118-5. [DOI] [PubMed] [Google Scholar]
  34. Mullane K. M., Bradley G., Moncada S. The interactions of platelet-derived mediators on isolated canine coronary arteries. Eur J Pharmacol. 1982 Oct 15;84(1-2):115–118. doi: 10.1016/0014-2999(82)90166-2. [DOI] [PubMed] [Google Scholar]
  35. Nunez D., Chignard M., Korth R., Le Couedic J. P., Norel X., Spinnewyn B., Braquet P., Benveniste J. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur J Pharmacol. 1986 Apr 16;123(2):197–205. doi: 10.1016/0014-2999(86)90660-6. [DOI] [PubMed] [Google Scholar]
  36. Parente L., Flower R. J. Hydrocortisone and 'macrocortin' inhibit the zymosan-induced release of lyso-PAF from rat peritoneal leucocytes. Life Sci. 1985 Apr 1;36(13):1225–1231. doi: 10.1016/0024-3205(85)90266-8. [DOI] [PubMed] [Google Scholar]
  37. Pinckard R. N., Farr R. S., Hanahan D. J. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol. 1979 Oct;123(4):1847–1857. [PubMed] [Google Scholar]
  38. Piper P. J., Stewart A. G. Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol. 1986 Jul;88(3):595–605. doi: 10.1111/j.1476-5381.1986.tb10240.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Schiffmann E., Corcoran B. A., Wahl S. M. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A. 1975 Mar;72(3):1059–1062. doi: 10.1073/pnas.72.3.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schrör K., Moncada S., Ubatuba F. B., Vane J. R. Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin. Eur J Pharmacol. 1978 Jan 1;47(1):103–114. doi: 10.1016/0014-2999(78)90380-1. [DOI] [PubMed] [Google Scholar]
  41. Sun F. F., McGuire J. C., Kane K., Feinmark S. J. Enzymatic reactions of leukotriene biosynthesis in human polymorphonuclear leukocytes. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:181–183. [PubMed] [Google Scholar]
  42. Sybertz E. J., Watkins R. W., Baum T., Pula K., Rivelli M. Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog. J Pharmacol Exp Ther. 1985 Jan;232(1):156–162. [PubMed] [Google Scholar]
  43. Sánchez-Crespo M., Fernández-Gallardo S., Nieto M. L., Baranès J., Braquet P. Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of paf-acether. Immunopharmacology. 1985 Oct;10(2):69–75. doi: 10.1016/0162-3109(85)90031-1. [DOI] [PubMed] [Google Scholar]
  44. Terashita Z., Imura Y., Nishikawa K., Sumida S. Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol. 1985 Feb 26;109(2):257–261. doi: 10.1016/0014-2999(85)90427-3. [DOI] [PubMed] [Google Scholar]
  45. Terashita Z., Tsushima S., Yoshioka Y., Nomura H., Inada Y., Nishikawa K. CV-3988 - a specific antagonist of platelet activating factor (PAF). Life Sci. 1983 Apr 25;32(17):1975–1982. doi: 10.1016/0024-3205(83)90049-8. [DOI] [PubMed] [Google Scholar]
  46. Touvay C., Etienne A., Braquet P. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. Agents Actions. 1986 Jan;17(3-4):371–372. doi: 10.1007/BF01982650. [DOI] [PubMed] [Google Scholar]
  47. Voelkel N. F., Worthen S., Reeves J. T., Henson P. M., Murphy R. C. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science. 1982 Oct 15;218(4569):286–289. doi: 10.1126/science.7123233. [DOI] [PubMed] [Google Scholar]
  48. Watts I. S., Zakrzewski J. T., Bakhle Y. S. Altered prostaglandin synthesis in isolated lungs of rats with streptozotocin-induced diabetes. Thromb Res. 1982 Nov 1;28(3):333–342. doi: 10.1016/0049-3848(82)90115-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES